Crystalloids vs Albumin Prime Solution and Postoperative Pulmonary Complications

NCT04839432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-04-27

No results posted yet for this study

Summary

In 2019, the investigators initiated a new priming fluid therapy strategy in the cardiopulmonary bypass (CPB) machine for patients undergoing pulmonary endarterectomy surgery. It consisted in a transition from a "pure" primarly balanced crystalloid priming fluid strategy to a 4% human albumin priming fluid-strategy in addition to a low volume of balanced crystalloid solution. The rationale was the theoritical assumption that albumin leads to better intravascular volume expansion compared to crystalloid and therefore could reduce overall volume requirement during surgery and consequently potentially decrease the incidence of postoperative pulmonary complications. The objective of this propensity-matched study was to evaluate the effectiveness of this intervention

Conditions

  • Postoperative Complications

Interventions

BEHAVIORAL

implementation of albumin solution in the priming of the cardiopulmonary bypass machine

In March 2019, the investigators initiated a new priming fluid policy strategy aiming at replacing our traditional pure crystalloid fluid administration for an albumin one in order to decrease the relatively high-rate of observed pulmonary complications

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Amelie Delaporte, MD · Marie lannelongue

Eligibility

Min Age
14 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2019-12-31
Completion
2020-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839432 on ClinicalTrials.gov